Adding Bevacizumab Has No Impact on Quality of Life in Glioblastoma
the Cancer Therapy Advisor take:
Adding bevacizumab to standard-of-care treatment of newly diagnosed glioblastoma during a progression-free period may have no impact on health-related quality of life, according to a recent study published online ahead of print in the Journal of Clinical Oncology.
Researchers led by Martin Taphoorn, MD, PhD, of the Medical Center Haaglanden in the Netherlands examined patients who completed the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires C30 and BN20 upon each tumor assessment. They converted raw scores to a 100-point scale and evaluated mean changes from baseline scores.
The researchers found that mean changes from baseline did not reach clinically relevant differences in observed patients compared to placebo. Adding bevacizumab to radiotherapy with temozolomide (RT/TMZ) resulted in statistically longer deterioration-free survival across all health-related quality of life items.
Time to deterioration was also found to not be statistically longer in the placebo plus RT/TMZ group.
“The addition of bevacizumab to standard-of-care treatment for newly diagnosed glioblastoma had no impact on health-related quality of life during the progression-free period,” the authors concluded.
Adding bevacizumab to standard treatment of glioblastoma may have no impact on health-related quality of life.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma